Multidrug-resistant tuberculosis treatment with linezolid-containing regimen

Maham Farshidpour; Golnaz Ebrahimi; Mehdi Mirsaeidi

doi:10.1016/j.ijmyco.2013.09.002

Multidrug-resistant tuberculosis treatment with linezolid-containing regimen

Int J Mycobacteriol. 2013 Dec 1;2(4):233-236. doi: 10.1016/j.ijmyco.2013.09.002.

Authors

Maham Farshidpour¹, Golnaz Ebrahimi², Mehdi Mirsaeidi³

Affiliations

¹ Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
² Division of Pulmonary and Critical Care, University of Illinois at Chicago, IL, USA.
³ Section of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine M/C 719, University of Illinois at Chicago, USA.

Abstract

The following is a case of multidrug-resistant pulmonary tuberculosis (MDR-TB) that was treated successfully with a linezolid-containing regimen. It was found that linezolid is an efficient medicine for MDR-TB treatment with an acceptable side effect profile. Treatment was maintained for 18 months, and closely monitoring toxicities did not reveal evidence of any neurologic adverse effects. However, despite our expectation, thrombocytopenia was seen after 2 years follow-up.

Keywords: Linezolid; Multidrug-resistant tuberculosis; Thrombocytopenia; Treatment.

Grants and funding

T32 HL082547/HL/NHLBI NIH HHS/United States